BioCentury | Jul 11, 2011
Finance

Making Merrimack

...stake); investment bank Credit Suisse (6.2%); mutual fund investor Fred Alger (5.6%); and hedge fund TPG-Axon...
BioCentury | Feb 2, 2009
Strategy

Valuing the upside

...million in Lexiscan royalties for the nine months ended Sept. 30, its April deal with TPG-Axon...
BioCentury | Sep 8, 2008
Strategy

Motivation for Medivation

...from Eli Lilly and Co. in Phase III testing. The company partnered the compound with TPG-Axon...
BioCentury | Sep 1, 2008
Strategy

Back to School 2008: Adversity & acclimatization

...is not limited to biotechs. Earlier this year, Lilly did a deal with hedge fund TPG-Axon...
...with additional resources to develop its Alzheimer’s molecules, while maintaining strategic control of its assets. TPG-Axon...
BioCentury | Aug 4, 2008
Finance

Ebb & Flow

...pulled a play from the biotech book when it did a deal with hedge fund TPG-Axon...
...Phase III trials for the two compounds, NovaQuest SVP Tom Perkins told Ebb & Flow. TPG-Axon...
...on advancing additional molecules in its pipeline. NovaQuest, which gets a fee, was established by TPG-Axon...
BioCentury | Jul 31, 2008
Targets & Mechanisms

Cleaving Schizophrenia

...III testing to treat AD. Last week, the company announced a $300 million deal with TPG-Axon...
...York at Stony Brook , Stony Brook, N.Y. TorreyPines Therapeutics Inc. (NASDAQ:TPTX), La Jolla, Calif. TPG-Axon...
BioCentury | Jul 28, 2008
Company News

Eli Lilly, TPG-Axon Capital Management L.P., Quintiles deal

...secretase inhibitor LY450139 and an unnamed antibody against beta amyloid to treat Alzheimer’s disease (AD). TPG-Axon...
...resources on advancing additional molecules in its pipeline. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. TPG-Axon...
BioCentury | Jul 26, 2008
Company News

Lilly secures funding for AD trials

...secretase inhibitor LY450139 and an unnamed antibody against beta amyloid to treat Alzheimer's disease (AD). TPG-Axon...
BioCentury | Jul 7, 2008
Finance

3Q Financial Markets Preview: Disquieting murmurs

...very good tool for financing.” Prominent among these types of deals was the $185 million TPG-Axon...
BioCentury | Jun 30, 2008
Company News

CV Therapeutics, Astellas, TPG-Axon Capital sales and marketing update

...payment from TPG-Axon to CV Therapeutics under a deal announced earlier this year that granted TPG-Axon...
...year end. CV Therapeutics Inc. (NASDAQ:CVTX), Palo Alto, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan TPG-Axon...
Items per page:
1 - 10 of 18
BioCentury | Jul 11, 2011
Finance

Making Merrimack

...stake); investment bank Credit Suisse (6.2%); mutual fund investor Fred Alger (5.6%); and hedge fund TPG-Axon...
BioCentury | Feb 2, 2009
Strategy

Valuing the upside

...million in Lexiscan royalties for the nine months ended Sept. 30, its April deal with TPG-Axon...
BioCentury | Sep 8, 2008
Strategy

Motivation for Medivation

...from Eli Lilly and Co. in Phase III testing. The company partnered the compound with TPG-Axon...
BioCentury | Sep 1, 2008
Strategy

Back to School 2008: Adversity & acclimatization

...is not limited to biotechs. Earlier this year, Lilly did a deal with hedge fund TPG-Axon...
...with additional resources to develop its Alzheimer’s molecules, while maintaining strategic control of its assets. TPG-Axon...
BioCentury | Aug 4, 2008
Finance

Ebb & Flow

...pulled a play from the biotech book when it did a deal with hedge fund TPG-Axon...
...Phase III trials for the two compounds, NovaQuest SVP Tom Perkins told Ebb & Flow. TPG-Axon...
...on advancing additional molecules in its pipeline. NovaQuest, which gets a fee, was established by TPG-Axon...
BioCentury | Jul 31, 2008
Targets & Mechanisms

Cleaving Schizophrenia

...III testing to treat AD. Last week, the company announced a $300 million deal with TPG-Axon...
...York at Stony Brook , Stony Brook, N.Y. TorreyPines Therapeutics Inc. (NASDAQ:TPTX), La Jolla, Calif. TPG-Axon...
BioCentury | Jul 28, 2008
Company News

Eli Lilly, TPG-Axon Capital Management L.P., Quintiles deal

...secretase inhibitor LY450139 and an unnamed antibody against beta amyloid to treat Alzheimer’s disease (AD). TPG-Axon...
...resources on advancing additional molecules in its pipeline. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. TPG-Axon...
BioCentury | Jul 26, 2008
Company News

Lilly secures funding for AD trials

...secretase inhibitor LY450139 and an unnamed antibody against beta amyloid to treat Alzheimer's disease (AD). TPG-Axon...
BioCentury | Jul 7, 2008
Finance

3Q Financial Markets Preview: Disquieting murmurs

...very good tool for financing.” Prominent among these types of deals was the $185 million TPG-Axon...
BioCentury | Jun 30, 2008
Company News

CV Therapeutics, Astellas, TPG-Axon Capital sales and marketing update

...payment from TPG-Axon to CV Therapeutics under a deal announced earlier this year that granted TPG-Axon...
...year end. CV Therapeutics Inc. (NASDAQ:CVTX), Palo Alto, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan TPG-Axon...
Items per page:
1 - 10 of 18